Meanwhile, Bermejo et al. and Vigón et al. found that the frequency of proviral integration was strongly reduced in activated CD4+ T cells from CML patients treated with dasatinib compared with those from untreated healthy donors [88,93]. The gene discussed is CD4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.